Everest Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Everest Medicines has a total shareholder equity of CN¥5.0B and total debt of CN¥539.2M, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are CN¥5.8B and CN¥804.1M respectively.
Key information
10.9%
Debt to equity ratio
CN¥539.24m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.35b |
| Equity | CN¥4.97b |
| Total liabilities | CN¥804.10m |
| Total assets | CN¥5.77b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6HN's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥300.1M).
Long Term Liabilities: 6HN's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥504.0M).
Debt to Equity History and Analysis
Debt Level: 6HN has more cash than its total debt.
Reducing Debt: 6HN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 6HN has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6HN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.